Jpmorgan Chase & CO Y M Abs Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 247,442 shares of YMAB stock, worth $2.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
247,442
Previous 97,660 153.37%
Holding current value
$2.13 Million
Previous $764,000 43.46%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$4.43 - $8.17 $663,534 - $1.22 Million
149,782 Added 153.37%
247,442 $1.1 Million
Q4 2024

Feb 12, 2025
BUY
$7.76 - $15.69 $522,442 - $1.06 Million
67,325 Added 221.94%
97,660 $764,000
Q3 2024

Dec 26, 2024
BUY
$9.95 - $15.39 $28,397 - $43,923
2,854 Added 10.39%
30,335 $398,000
Q3 2024

Nov 08, 2024
BUY
$9.95 - $15.39 $28,397 - $43,923
2,854 Added 10.39%
30,335 $398,000
Q2 2024

Dec 26, 2024
SELL
$11.6 - $17.25 $33,106 - $49,231
-2,854 Reduced 9.41%
27,481 $331,000
Q2 2024

Aug 12, 2024
SELL
$11.6 - $17.25 $42,769 - $63,600
-3,687 Reduced 11.83%
27,481 $331,000
Q1 2024

Dec 26, 2024
BUY
$6.57 - $18.69 $5,472 - $15,568
833 Added 2.75%
31,168 $506,000
Q1 2024

May 10, 2024
SELL
$6.57 - $18.69 $66,987 - $190,563
-10,196 Reduced 24.65%
31,168 $506,000
Q4 2023

Dec 26, 2024
BUY
$4.88 - $7.42 $53,821 - $81,835
11,029 Added 36.36%
41,364 $282,000
Q4 2023

Feb 12, 2024
BUY
$4.88 - $7.42 $43,144 - $65,600
8,841 Added 27.18%
41,364 $282,000
Q3 2023

Nov 14, 2023
SELL
$4.86 - $7.23 $29,160 - $43,380
-6,000 Reduced 15.58%
32,523 $177,000
Q2 2023

Aug 11, 2023
SELL
$5.68 - $10.34 $891,260 - $1.62 Million
-156,912 Reduced 80.29%
38,523 $261,000
Q1 2023

May 18, 2023
BUY
$2.83 - $5.11 $79,593 - $143,718
28,125 Added 16.81%
195,435 $979,000
Q1 2023

May 11, 2023
BUY
$2.83 - $5.11 $380,994 - $687,943
134,627 Added 411.92%
167,310 $838,000
Q4 2022

Feb 13, 2023
SELL
$3.0 - $15.17 $3,888 - $19,660
-1,296 Reduced 3.81%
32,683 $160,000
Q3 2022

Nov 14, 2022
BUY
$13.96 - $19.67 $18,357 - $25,866
1,315 Added 4.03%
33,979 $491,000
Q2 2022

Aug 11, 2022
SELL
$8.22 - $15.13 $79,388 - $146,125
-9,658 Reduced 22.82%
32,664 $494,000
Q1 2022

May 11, 2022
BUY
$6.55 - $17.42 $31,125 - $82,779
4,752 Added 12.65%
42,322 $503,000
Q4 2021

Feb 10, 2022
BUY
$15.51 - $29.31 $26,211 - $49,533
1,690 Added 4.71%
37,570 $610,000
Q3 2021

Nov 12, 2021
BUY
$27.47 - $37.31 $985,623 - $1.34 Million
35,880 New
35,880 $1.02 Million

Others Institutions Holding YMAB

# of Institutions
96
Shares Held
25.9M
Call Options Held
24K
Put Options Held
0
View Full List

About Y-mAbs Therapeutics, Inc.

YMAB Quotes by TradingView
  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $376M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email